Global Transthyretin Stabilizer Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Transthyretin Stabilizer Market Research Report 2024
Transthyretin found in serum and cerebrospinal fluid of body is one of the transport protein carrying thyroxine and retinol-binding proteins. Transthyretin destabilization can take place due to inherited mutations or ageing.Transthyretin stabilizers prevent destabilization of protein and amyloidosis progression.A transthyretin (TTR) stabilizer is a type of medication or compound that is used in the treatment of transthyretin amyloidosis (ATTR), a rare genetic disorder characterized by the deposition of abnormal TTR protein in various organs and tissues.
TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.
According to Mr Accuracy reports new survey, global Transthyretin Stabilizer market is projected to reach US$ 2372.8 million in 2029, increasing from US$ 1480 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Transthyretin Stabilizer market research.
The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.
Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.
One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.
The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.
Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.
Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.
In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Transthyretin Stabilizer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.
Segment by Type
Diflunisal
Tafamidis
Others
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Transthyretin Stabilizer report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
TTR stabilizers work by binding to and stabilizing the TTR protein, preventing it from misfolding and forming amyloid fibrils. By stabilizing the TTR protein, these medications aim to slow down or halt the progression of the disease and potentially alleviate symptoms.
According to Mr Accuracy reports new survey, global Transthyretin Stabilizer market is projected to reach US$ 2372.8 million in 2029, increasing from US$ 1480 million in 2022, with the CAGR of 6.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Transthyretin Stabilizer market research.
The global transthyretin stabilizer market refers to the market for medications and compounds used in the treatment of transthyretin amyloidosis (ATTR) by stabilizing the transthyretin (TTR) protein. This market encompasses various drugs that have been developed or under development as TTR stabilizers.
Currently, there are several TTR stabilizers that have gained regulatory approval or are in advanced stages of clinical development. The market is primarily driven by the rising prevalence of ATTR, increasing awareness of the disease, and the need for effective treatment options.
One of the key drugs in the market is tafamidis, which is approved in several countries for the treatment of ATTR polyneuropathy. Tafamidis has shown to stabilize TTR and slow disease progression in clinical trials. Other drugs such as diflunisal, AG10, inotersen, and patisiran are also being investigated and have shown promising results in clinical studies.
The market is expected to witness significant growth as more research is conducted on the development of TTR stabilizers and as regulatory approvals are obtained for these drugs in different regions. Additionally, the ongoing efforts to increase disease awareness among healthcare professionals and patients are likely to contribute to the market growth.
Key players in the global transthyretin stabilizer market include pharmaceutical companies such as Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, and Ionis Pharmaceuticals Inc., among others. These companies invest in research and development activities to develop new TTR stabilizers and expand their product portfolios.
Geographically, North America and Europe are leading regions in the market, primarily due to the higher prevalence of ATTR and the presence of established healthcare infrastructure. However, as awareness and diagnosis of ATTR improve in other regions such as Asia Pacific and Latin America, these regions are likely to exhibit significant growth opportunities.
In conclusion, the global transthyretin stabilizer market is expected to grow as more effective treatments are developed and approved for ATTR. The market is driven by the increasing prevalence of the disease and the need for therapies that can stabilize the TTR protein and slow disease progression.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Transthyretin Stabilizer market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer Inc.
Merck & Co.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Corino Therapeutics Inc.
Alnylam Pharmaceuticals
Bellus Health Inc.
Ionis Pharmaceuticals, Inc.
Proclara Bioscience
Arturus Therapeutics
Prothena Corporation Plc.
Segment by Type
Diflunisal
Tafamidis
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Transthyretin Stabilizer report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices